Our top pick for
Mustang Bio, Inc is a biotechnology business based in the US. Mustang Bio shares (MBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Mustang Bio employs 51 staff and has a market cap (total outstanding shares value) of USD$219.9 million.
|52-week range||USD$1.78 - USD$4.85|
|50-day moving average||USD$3.0201|
|200-day moving average||USD$3.2398|
|Wall St. target price||USD$9|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.325|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-38.25%|
|Return on equity TTM||-80.1%|
|Market capitalisation||USD$219.9 million|
TTM: trailing 12 months
There are currently 4.3 million Mustang Bio shares held short by investors – that's known as Mustang Bio's "short interest". This figure is 45% up from 3.0 million last month.
There are a few different ways that this level of interest in shorting Mustang Bio shares can be evaluated.
Mustang Bio's "short interest ratio" (SIR) is the quantity of Mustang Bio shares currently shorted divided by the average quantity of Mustang Bio shares traded daily (recently around 1.6 million). Mustang Bio's SIR currently stands at 2.67. In other words for every 100,000 Mustang Bio shares traded daily on the market, roughly 2670 shares are currently held short.
However Mustang Bio's short interest can also be evaluated against the total number of Mustang Bio shares, or, against the total number of tradable Mustang Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mustang Bio's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Mustang Bio shares in existence, roughly 70 shares are currently held short) or 0.0881% of the tradable shares (for every 100,000 tradable Mustang Bio shares, roughly 88 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Mustang Bio.
Find out more about how you can short Mustang Bio stock.
We're not expecting Mustang Bio to pay a dividend over the next 12 months.
Over the last 12 months, Mustang Bio's shares have ranged in value from as little as $1.78 up to $4.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mustang Bio's is 1.6001. This would suggest that Mustang Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase 1/2 clinical trials. The company also develops MB-102, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; MB-106 for immunotherapy of B-cell lymphomas; MB-104, an NK cell receptor regulating immune functions; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has a license agreement with Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center, Inc. to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.